This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Harvey R. Gralnick, MD; Pascal Maisonneuve, MD; Yvette Sultan, MD; Margaret E. Rick, MD

JAMA. 1985;253(8):1151-1153.

Abstract
Danazol, an attenuated androgen, was given intermittently to three patients with hemophilia A. The rise in factor VIII activity with danazol treatment was associated with a fivefold decrease in hemorrhagic episodes and plasma concentrate product utilization when compared with similar periods without the drug. Four other patients with moderate hemophilia A who received danazol for 14 days had an increase of 400% to 850% in their factor VIII levels. Of four patients without detectable levels of factor VIII who were treated with danazol, two had elevations of the factor VIII level, to 3% and 4%, respectively. Danazol appears to be an effective treatment for patients with hemophilia A.

(JAMA 1985;253:1151-1153)

Author Affiliations
From the Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, Md (Drs Gralnick and Rick); and Laboratoire d'Hemostase, Hospital Cochin, Paris (Drs Maisonneuve and Sultan).

Footnotes
Reprint requests to Chief, Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bldg 10, Room 2C390, Bethesda, MD 20205 (Dr Gralnick).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Prophylactic Treatment of Hemophilia B Leyden with Anabolic Steroids
BRIET et al.
ANN INTERN MED 1985;103:225-226.
ABSTRACT  

Danazol and Hemophilia
Hathaway
JAMA 1985;253:1167-1167.
ABSTRACT